The discovery of avanafil for the treatment of erectile dysfunction: A novel pyrimidine-5-carboxamide derivative as a potent and highly selective phosphodiesterase 5 inhibitor-Reference-Cited by-同舟云学术

The discovery of avanafil for the treatment of erectile dysfunction: A novel pyrimidine-5-carboxamide derivative as a potent and highly selective phosphodiesterase 5 inhibitor

Published:2014-12 Issue:23 Volume:24 Page:5460-5465
ISSN:0960-894X
Container-title:Bioorganic & Medicinal Chemistry Letters
language:en
Short-container-title:Bioorganic & Medicinal Chemistry Letters

Author:

Sakamoto Toshiaki,Koga Yuichi,Hikota Masataka,Matsuki Kenji,Murakami Michino,Kikkawa Kohei,Fujishige Kotomi,Kotera Jun,Omori Kenji,Morimoto Hiroshi,Yamada Koichiro

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference10 articles.

1. An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors

2. Overview of PDEs and Their Regulation

3. Sildenafil (Viagra) and Ophthalmology

4. Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database

5. Characteristics of Photoreceptor PDE (PDE6): similarities and differences to PDE5

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthetic approaches and clinical application of representative small-molecule inhibitors of phosphodiesterase;European Journal of Medicinal Chemistry;2024-11

2. The role of the methoxy group in approved drugs;European Journal of Medicinal Chemistry;2024-07

3. Inflammation in cerebral ischemia reperfusion improved by avanafil via nod-like receptor protein-3 inflammasome: an experimental study in rats;Brain Injury;2024-04-27

4. Analytical methods for the detection and characterization of unapproved phosphodiesterase type 5 inhibitors (PDE-5i) used in adulteration of dietary supplements- a review;Food Additives & Contaminants: Part A;2023-11-27

5. Advancements in Phosphodiesterase 5 Inhibitors: Unveiling Present and Future Perspectives;Pharmaceuticals;2023-09-06